as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 17 Nov 2026
₹5,834.0
Change
-161.5 (-2.69%)
Open
₹5,995.5
Prev. Close
₹5,995.5
Day High
₹5,997.0
Day Low
₹5,757.0
Volume Analysis
Traded
2,654
Delivered
1,903
Delivery %
71.7%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Promoter holding is rising
- •Strong operating margin (31.0%)
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (22.7%)
- •Strong 3-year revenue growth (20.7%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹6,208.34 | ₹6,102.67 | ₹5,968.34 | ₹5,862.67 | ₹5,728.34 | ₹5,622.67 | ₹5,488.34 |
| Fibonacci | ₹6,102.67 | ₹6,010.99 | ₹5,954.35 | ₹5,862.67 | ₹5,770.99 | ₹5,714.35 | ₹5,622.67 |
| Camarilla | ₹5,900.0 | ₹5,878.0 | ₹5,856.0 | ₹5,862.67 | ₹5,812.0 | ₹5,790.0 | ₹5,768.0 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-3.18%
1 Month
+16.44%
3 Months
+8.14%
6 Months
+12.74%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
20.03%
Net margin 14.86% × asset turnover 0.61x × equity multiplier 2.21x
Company Overview
Sector
Healthcare
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Dr. Agarwal's Eye Hosp L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 78/100. The strongest factor is Growth (100/100), while Liquidity (52/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (31.0%). Strong 3-year EPS growth (22.7%).
TopFund Score — Fundamentals Quality
78/100 — GoodData confidence: 73/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 17 Nov 2026 · How we calculate this →
Financial Strength
Growth
Cash Flow
Corporate Governance
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Record date set for Nov 18, 2026; shareholders get 23 AHCL shares for 2 AEHL shares.
NCLT-sanctioned amalgamation effective November 1, 2026; record date November 18, 2026 for share exchange.
Disclosure under Regulation 74(5) of the SEBI (DP) Regulations, 2018, is submitted.
NCLT sanctioned amalgamation of AEHL into AHCL; effective from April 1, 2026, pending conditions.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 (S) | Sep 2023 (S) | Dec 2023 (S) | Mar 2024 (S) | Jun 2024 (S) | Sep 2024 (S) | Dec 2024 (S) | Mar 2025 (S) | Jun 2025 (S) | Sep 2025 (S) | Dec 2025 (S) | Mar 2026 (S) | Jun 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 79 | 84 | 76 | 81 | 100 | 102 | 95 | 100 | 117 | 118 | 116 | 120 | 143 |
| Expenses + | 56 | 61 | 55 | 56 | 69 | 72 | 69 | 68 | 80 | 78 | 82 | 86 | 100 |
| Operating Profit | 23 | 23 | 21 | 24 | 31 | 30 | 26 | 32 | 37 | 40 | 34 | 34 | 43 |
| OPM % | 29.0% | 28.0% | 27.0% | 30.0% | 31.0% | 29.0% | 27.0% | 32.0% | 32.0% | 34.0% | 30.0% | 28.0% | 30.0% |
| Other Income + | 0 | 1 | 1 | 2 | 0 | 2 | 2 | 0 | 1 | 1 | 3 | 2 | 2 |
| Interest | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 3 | 4 | 4 | 2 | 2 | 3 |
| Depreciation | 6 | 6 | 7 | 8 | 10 | 9 | 10 | 10 | 11 | 11 | 12 | 12 | 11 |
| Profit before tax | 16 | 17 | 13 | 17 | 19 | 19 | 14 | 19 | 23 | 26 | 23 | 21 | 31 |
| Tax % | 26.0% | 24.0% | 26.0% | 26.0% | 25.0% | 26.0% | 26.0% | 14.0% | 26.0% | 25.0% | 26.0% | 24.0% | 24.0% |
| Net Profit + | 12 | 13 | 9 | 13 | 14 | 14 | 10 | 16 | 17 | 19 | 17 | 16 | 23 |
| EPS in Rs | 25 | 27 | 20 | 27 | 30 | 30 | 22 | 34 | 37 | 40 | 36 | 34 | 48 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 18 | 22 | 20 | 16 | 27 | 22 | 25 | 24 | 17 | 15 | 22 | 20 | 22 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 118 | 137 | 149 | 153 | 170 | 176 | 140 | 201 | 268 | 319 | 397 | 471 |
| Expenses + | 103 | 119 | 126 | 129 | 140 | 129 | 109 | 143 | 192 | 227 | 277 | 324 |
| Operating Profit | 15 | 18 | 23 | 24 | 30 | 47 | 31 | 59 | 76 | 92 | 120 | 147 |
| OPM % | 13.0% | 13.0% | 15.0% | 16.0% | 18.0% | 27.0% | 22.0% | 29.0% | 28.0% | 29.0% | 30.0% | 31.0% |
| Other Income + | 0 | -5 | 1 | 2 | 2 | 3 | 1 | 1 | 2 | 5 | 5 | 6 |
| Interest | 4 | 5 | 4 | 3 | 4 | 9 | 7 | 7 | 8 | 8 | 15 | 14 |
| Depreciation | 6 | 9 | 9 | 10 | 11 | 21 | 19 | 20 | 20 | 27 | 39 | 46 |
| Profit before tax | 5 | 0 | 11 | 13 | 17 | 20 | 6 | 32 | 49 | 62 | 71 | 94 |
| Tax % | -6.0% | -104.0% | 33.0% | 49.0% | 32.0% | 31.0% | 125.0% | 25.0% | 25.0% | 26.0% | 23.0% | 25.0% |
| Net Profit + | 6 | 0 | 7 | 7 | 12 | 14 | -1 | 24 | 37 | 46 | 55 | 70 |
| EPS in Rs | 12 | 0 | 16 | 14 | 25 | 29 | -3 | 51 | 79 | 99 | 116 | 145 |
| Dividend Payout % | 10.0% | 940.0% | 10.0% | 8.0% | 6.0% | 0.0% | 0.0% | 6.0% | 4.0% | 3.0% | 5.0% | 5.0% |
| Sales growth | 5 | 16 | 9 | 3 | 11 | 3 | -21 | 44 | 33 | 19 | 24 | 19 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 19 | 19 | 25 | 30 | 41 | 51 | 50 | 73 | 109 | 152 | 205 | 341 |
| Borrowings + | 27 | 31 | 23 | 18 | 24 | 60 | 68 | 193 | 232 | 268 | 333 | 326 |
| Other Liabilities + | 18 | 24 | 20 | 28 | 31 | 24 | 33 | 42 | 44 | 71 | 71 | 94 |
| Total Liabilities | 69 | 79 | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 | 766 |
| Fixed Assets + | 26 | 34 | 33 | 36 | 55 | 94 | 96 | 214 | 260 | 316 | 393 | 403 |
| CWIP | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 26 | 62 | 97 | 128 | 197 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 89 |
| Other Assets + | 43 | 44 | 38 | 42 | 45 | 47 | 60 | 73 | 67 | 83 | 80 | 78 |
| Total Assets | 69 | 79 | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 | 766 |
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 14 | 17 | 20 | 19 | 25 | 39 | 34 | 57 | 70 | 90 | 94 | 145 |
| Cash from Investing Activity + | -10 | -17 | -8 | -11 | -25 | -17 | -11 | -46 | -71 | -70 | -133 | -174 |
| Cash from Financing Activity + | -5 | 0 | -12 | -8 | 2 | -20 | -8 | -4 | 0 | -14 | 17 | 25 |
| Net Cash Flow | -1 | 0 | 0 | 0 | 2 | 2 | 15 | 7 | -1 | 6 | -23 | -4 |
| Free Cash Flow | 3 | 1 | 12 | 7 | 0 | 22 | 23 | 10 | -1 | 19 | -9 | 47 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 106 | 113 | 103 | 98 | 111 | 96 | 120 | 112 | 107 | 112 | 95 | 105 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 27.47% | 27.47% | 27.46% | 26.32% | 26.22% | 24.82% | 24.29% | 23.22% | 23.15% | 22.99% | 23.03% | 22.56% |
| Promoters | 71.89% | 71.89% | 71.9% | 71.9% | 71.9% | 71.9% | 71.9% | 72.67% | 72.67% | 72.67% | 72.67% | 72.67% |
| FII | 0.63% | 0.64% | 0.65% | 0.83% | 0.84% | 1.33% | 1.49% | 1.74% | 1.82% | 2.2% | 2.24% | 2.22% |
| DII | 0.0% | 0.0% | 0.0% | 0.96% | 1.04% | 1.95% | 2.31% | 2.36% | 2.36% | 2.12% | 2.05% | 2.54% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Dr. Agarwal's Eye Hosp L (this stock) | — | — | — | — |
| Sun Pharmaceutical Ind L | 451,075 | 36.7 | 5.05 | 16.0% |
| Divi S Laboratories Ltd | 294,139 | 86.1 | 16.34 | 16.5% |
| Torrent Pharmaceuticals L | 177,632 | 81.8 | 9.67 | 27.4% |
| Apollo Hospitals Enter. L | 125,893 | 55.6 | 11.86 | 21.5% |
| Laurus Labs Limited | 125,380 | 93.6 | 20.73 | 18.3% |
| Zydus Lifesciences Ltd | 118,693 | 26.2 | 4.27 | 21.2% |
Which Mutual Funds Hold Dr. Agarwal's Eye Hosp L?
Frequently Asked Questions about Dr. Agarwal's Eye Hosp L
Dr. Agarwal's Eye Hosp L (DRAGARWQ) closed at ₹5,834.0 on NSE on 17 November 2026, down 161.5 (2.69%) from the previous close.
Dr. Agarwal's Eye Hosp L trades on the NSE (National Stock Exchange of India) under the symbol DRAGARWQ.
Dr. Agarwal's Eye Hosp L has a TopFund Quality Score of 78/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Dr. Agarwal's Eye Hosp L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.